Comparison of a selective STAT3 inhibitor with a dual STAT3/STAT1 inhibitor using a dextran sulfate sodium murine colitis model: new insight into the debate on selectivity.
Fiche publication
Date publication
avril 2024
Journal
Annals of gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
Tous les auteurs :
Moulari B, Pallandre JR, Béduneau A, Borg C, Pellequer Y, Pudlo M
Lien Pubmed
Résumé
Recent advances in the treatment of inflammatory bowel disease include antitumor necrosis factor antibodies and the Janus kinase inhibitor tofacitinib, approved for ulcerative colitis. Janus kinase recruits signal transducers and activators of transcriptions (STAT), which are promising targets in inflammatory bowel diseases. However few inhibitors have been evaluated, and their selectivity with respect to STAT1 and STAT3 remains controversial. Here, we investigated the therapeutic potential of a selective inhibitor vs. a non-selective, closely related compound, in a dextran sulfate sodium (DSS) murine colitis model.
Mots clés
Inflammatory bowel disease, dual inhibitor, signal transducers and activators of transcription 3, ulcerative colitis
Référence
Ann Gastroenterol. 2024 04 25;37(3):333-340